CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Mologen AG is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Mologen AG
Koenigin-Luise-Str. 27
Phone: +49 308417880p:+49 308417880 BERLIN, 14195  Germany Ticker: MGNKMGNK
Filed for Insolvency on 12/3/2019
On 12/3/2019, Mologen AG filed for Insolvency Proceedings in the District Court of Charlottenburg.
This company is no longer actively traded on any major stock exchange.
Business Summary
Mologen AG is a Germany-based company engaged in the biotechnology and medical research industry. The Company specializes in the research and development of drugs in the fields of oncology and infectious diseases. The Company develops medicines and vaccines on the basis of its MIDGE, dSLIM and EnanDIM platform technologies and through the use of its human, allogeneic tumor cell bank. Within the area of oncology, the Company develops Lefitolimod, which is intended to enable the patient's immune system to recognize the body's own cancer cells and fight them, MGN1601, which works like a therapeutic vaccination against cancer, as well as MGN1404, which is targeted at malignant melanoma. Within the area of infectious diseases, the Company develops deoxyribonucleic acid (DNA) vaccines against leishmaniasis and hepatitis B.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/201912/31/2018Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Supervisory Board OliverKrautscheid 53 8/13/2014 8/13/2014
Chief Executive Officer, Member of the Executive Board Stefan M.Manth 65 5/1/2019 8/13/2014
Member of the Supervisory Board GerhardGreif 6/17/2019 6/17/2019
Member of the Supervisory Board MichaelSchultz 6/8/2018 6/8/2018
Member of the Supervisory Board FriederikeZahm 8/30/2019 8/30/2019

Business Names
Business Name
0IYN
MGN
MGNK
Mologen AG
Mologen Holding AG

General Information
Number of Employees: 43 (As of 9/30/2019)
Outstanding Shares: 12,435,774 (As of 11/30/2019)
Shareholders: 17,073
Stock Exchange: HAM
Fax Number: +49 3084178850


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023